Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BLRX.TA
- Price
- 1.70
- Stock movement up
- +- (%)
- Company name
- BioLine RX Ltd
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.14B
- Ent value
- 2.19B
- Price/Sales
- 125.81
- Price/Book
- 153.41
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -22.52%
- 1 year return
- -93.95%
- 3 year return
- -63.01%
- 5 year return
- -47.74%
- 10 year return
- -56.54%
Last updated: 2025-04-09
DIVIDENDS
BLRX.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 125.81 |
| Price to Book | 153.41 |
| EV to Sales | 128.22 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.26B |
| EPS (TTM) | -0.03 |
| FCF per share (TTM) | -0.03 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 17.05M |
| Gross profit (TTM) | 9.90M |
| Operating income (TTM) | -34.82M |
| Net income (TTM) | -30.12M |
| EPS (TTM) | -0.03 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 58.05% |
| Operating margin (TTM) | -204.22% |
| Profit margin (TTM) | -176.67% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.62M |
| Net receivables | 3.18M |
| Total current assets | 49.11M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.80M |
| Total assets | 64.60M |
| Accounts payable | 6.27M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 30.52M |
| Total liabilities | 50.62M |
| Shareholder's equity | 13.98M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -30.35M |
| Capital expenditures (TTM) | 104.00K |
| Free cash flow (TTM) | -30.45M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -215.43% |
| Return on Assets | -46.63% |
| Return on Invested Capital | -91.91% |
| Cash Return on Invested Capital | -92.92% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.70 |
| Daily high | 1.70 |
| Daily low | 1.60 |
| Daily Volume | 4.80M |
| All-time high | 65010.00 |
| 1y analyst estimate | 3.00 |
| Beta | 0.87 |
| EPS (TTM) | -0.03 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BLRX.TA | S&P500 | |
| Current price drop from All-time high | -100.00% | -19.00% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -84.48% | -11.07% |
| Avg time to new high | 4452 days | 12 days |
| Max time to new high | 4451 days | 1805 days |
COMPANY DETAILS
Marketcap
2.14B
Marketcap category
Mid-cap
Description
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Employees
79
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported full-year 2024 results, with revenues reaching $28.9 million. As the company completes it...
April 3, 2025
BioLine Rx Ltd (BLRX) secures significant licensing deals and investments, while navigating operational challenges and focusing on oncology and rare diseases.
April 2, 2025
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results f...
March 31, 2025
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited ...
March 24, 2025
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) continues its commercialization transition activities for Aphexda as responsibilities for marketin...
February 19, 2025
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders...
January 21, 2025
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has a...
January 17, 2025
BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced...
January 6, 2025
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT A few days prior to its third quarter earnings report, BioLineRx Ltd. (NASDAQ:BLRX) announced a commercialization agreement wit...
December 3, 2024
BioLine Rx Ltd (BLRX) reports a significant revenue increase and outlines strategic plans amid operational changes and market challenges.
November 26, 2024
Next page